{"schema_version":"secwatch.filing_event.v1","accession":"0001410098-26-000054","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2026-08-13T11:32:23+00:00","discovered_at":"2026-08-13T11:35:00.261059+00:00","generated_at":"2026-08-13T11:35:07.723858+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CorMedix Q2 revenue $101.9M, net income $26.0M; raises FY26 adjusted EBITDA guidance","bullets":["Q2 2026 consolidated revenue of $101.9M; net income of $26.0M; adjusted EBITDA of $58.7M; diluted EPS $0.29.","DefenCath net revenue $66.1M; acquired Melinta portfolio contributed $35.8M.","FY26 revenue guidance maintained at $325-345M; adjusted EBITDA guidance raised to $125-140M.","New multi-year DefenCath supply agreement with an LDO; now covers all top 5 U.S. dialysis providers.","REZZAYO sNDA for prophylaxis of invasive fungal disease expected Q3 2026; FDA action anticipated H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001410098-26-000054","json":"https://secwatch.observer/filing/0001410098-26-000054.json","markdown":"https://secwatch.observer/filing/0001410098-26-000054.md","text":"https://secwatch.observer/filing/0001410098-26-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/0001410098-26-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:35:07.723858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}